Drugs / GS-3242
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07001319 | May 2025 → Mar 2026 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07841990 | Sep 2026 → Aug 2027 expected | HIV infectious disease | Gilead Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07645287 | Jun 2026 → Aug 2027 expected | HIV infectious disease | Gilead Sciences | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07708727 | Jul 2026 → Oct 2030 expected | HIV infectious disease | Gilead Sciences | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS-3242 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07645287 ↗ |
| Route | Oral | “Administered orally” NCT07001319 ↗ |